Company Update FY24
PT Kalbe Farma Tbk
April 2025
Table of Content
• | Key Updates | 04 |
• | Business Strategies | 08 |
• | Financial Overview | 23 |
• | Appendix 1 | 30 |
• | Appendix 2 | 37 |
Key Updates
More than Half a Century of Providing Wide-Range Healthcare Solutions
Market Capitalization
IDR 63.8 tn ($3.9 bn)*
free float
42.01%*
Corporate Overview
Indonesian integrated healthcare company with regional footprint
1966 | 1991 | Onwards |
Established, headquartered | Listed in the | The most integrated |
healthcare company in | ||
in Jakarta | Indonesia Stock Exchange | |
Southeast Asia | ||
Including treasury stocks
* As of 31 Dec 24
Prescription | |||
Pharmaceuticals | |||
33.4% | 28.3% | Consumer Health | |
Net Sales | |||
IDR 32,628 bn | |||
FY 2024 | Nutritionals | ||
(Audited) | |||
13.2% | |||
25.1% | Distribution & Logistics | ||
6%
Export
±40
Countries
Middle
EastSEA
South
Africa
Solid Foundation for Future Growth
Key Takeaways
Strategic Partnerships and Investments
7.2% | FY24 Audited | 17.3% | FY24 Audited |
Net Sales growth | EPS growth |
Strengthening product portfolio through collaboration
Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand)
Key Updates
- Positive organic top-line growth driven by volume
- Progressing on track in key projects to drive future growth
- Recovery of gross margin trend
- Driving marketing effectiveness to sustain growth
Key Risks
- Global financial and geopolitical volatility impact to currency and supply chain
- Pace of purchasing power recovery in domestic market
Zerpidio and Efesa commercialization
Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients
Radiopharmaceuticals facilities (cyclotron)
Local Content Requirement in medical devices for Dialyzer, Mobile X-Ray, CT- Scan, endoscopy, USG machine
Driving Growth and Improving Healthcare Resilience through Innovation
2025 Key Strategies
Investing for long term growth through innovation and collaboration
Prescription | Medical | International |
Pharmaceuticals | Devices | Market |
Consumer Health
& Nutritionals
Distribution
& Logistics
Innovative Biologics products, including expanding Insulin business and cell therapy
Strengthen our position in the market
Build local manufacturing capability
Strengthen network and collaboration
Bring more products to export markets
Focus on selected countries
Expand into preventive and wellness category
Strengthen nutritional presence in affordable and ready-to-drink categories
New potential principals
Strengthen medical and distribution channel
Strengthen portfolio in Vaccine
Accelerate technology transfer
Comply with local content requirements
Optimize Alliance Pharma to bring biologics product to Thai market
Business Strategies
Driving Top Line Growth with Portfolio Strategy
Prescription Pharmaceuticals
Building | Participation in | Enhance Business |
Specialty Portfolio | National Health | Growth |
Steadily growing specialty | Insurance | by leveraging on |
category with | Consistent growth | strong commercial |
expanding innovative | team and distribution | |
in E-Catalog | ||
portfolio, supported by | network | |
local manufacturing |
Strategic Collaborations to Accelerate Growth
Prescription Pharmaceuticals
Sustaining Business Expansion through Strategic Partnerships
Livzon Pharma Indonesia
Shareholder Agreement Signing Jul 2024
To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future
Exclusive Collaboration signing May 2024
To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand
JV establishment Dec 2022
To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar
Completion Dec 2022
To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines
Oncology
Biological-based
Other
Complete product range in all segments covering licensed, branded and unbranded generics
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |